UK midcap stocks hit record high ahead of Bank of England rate decision

Traders Union
All News
Stocks
UK midcap record before BoE

Highlights

FTSE 100 rises 0.5% to 10,888.64 and FTSE 250 adds 0.6% to a record high as markets anticipate a 25-basis-point Bank of England rate hike.
Precious metal miners surge 5% with gold prices at a two-week high, while pharmaceutical and energy shares fall 0.3% and 0.5%, respectively.
BT Group climbs 3.5% after beating Q2 revenue estimates; BAE Systems drops 4.1% on U.S. defence spending worries; Hikma Pharmaceuticals falls 6% after cutting profit outlook.

Rate decision focus lifts banks and broader indexes

As reported by Reuters, the FTSE 100 rises 0.5% to 10,888.64 points by 1034 GMT, while the FTSE 250 adds 0.6% to reach an all-time high. Markets widely expect the Bank of England to deliver a 25-basis-point increase on Thursday, which would mark its first rate rise in three years.

Investors are also weighing a broader global tightening cycle, with the U.S. Federal Reserve and the European Central Bank having already raised rates and further increases priced in. Britain's inflation holds at 3.5% in September, above the Bank of England's 2% target, according to data released last month.

Banking stocks build on Wednesday's rally and climb 1.3% to their highest level in more than a week. HSBC provides the biggest boost among lenders, advancing 1.2%.

Company moves show mixed sector impact

Precious metal miners jump 5%, supported by gold prices touching a two-week high after the sector posted its biggest one-day rise in three months in the previous session. By contrast, pharmaceutical and energy shares fall 0.3% and 0.5%, respectively.

BT Group gains 3.5% after beating second-quarter revenue estimates, helping lift the wider telecom sector by 1.2%. At the weaker end of the market, BAE Systems drops 4.1% and remains the biggest FTSE 100 faller after concerns that a Democratic sweep in the U.S. midterm elections could lead to tighter military spending.

Hikma Pharmaceuticals is the worst performer on the FTSE 250, sliding 6% after the drugmaker cuts the upper end of its annual profit forecast range.

Expectations for a Bank of England rate hike have firmed as inflation stays above target and recent UK data come in stronger than forecast. Our earlier report noted that most economists were looking for a 25-basis-point move to 4.0% in November, while remaining split on how far tightening would ultimately go. It also highlighted policymakers’ focus on inflation risks and the need to stay alert to market volatility even as the economy absorbs recent shocks better than initially expected.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.